The price of insulin icodec is not publicly disclosed by Novo Nordisk, the manufacturer. Pricing for new insulin products is often set closer to their market launch and can vary based on factors such as payer agreements, geographic location, and insurance coverage.
What is Insulin Icodec?
Insulin icodec is a novel, once-weekly basal insulin designed for people with diabetes. It is currently under development and has shown promise in clinical trials for its ability to maintain glycemic control with less frequent dosing compared to daily insulins [1].
How Does Insulin Icodec Compare to Other Insulins?
Insulin icodec is a long-acting basal insulin, meaning it provides a slow and steady release of insulin over an extended period. This contrasts with rapid-acting or short-acting insulins that are taken before meals to manage post-meal glucose spikes. Its primary advantage is the convenience of a once-weekly injection, aiming to reduce the treatment burden for patients [1]. Unlike daily basal insulins such as insulin glargine (Lantus, Toujeo) or insulin degludec (Tresiba), insulin icodec offers a less frequent dosing schedule.
When Could Insulin Icodec Be Available?
Novo Nordisk has submitted applications for regulatory approval of insulin icodec in the United States and Europe. The timeline for approval and subsequent market availability depends on the regulatory review process by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
What Clinical Trials Have Been Conducted for Insulin Icodec?
Insulin icodec has been evaluated in several Phase 3 clinical trials, including the ONWARDS program. These trials have assessed its efficacy and safety in diverse patient populations, comparing it against other basal insulins and placebo. Key trial findings have generally indicated that insulin icodec effectively lowers HbA1c levels while offering the benefit of once-weekly administration [1].
What Are the Potential Benefits of Once-Weekly Insulin?
The main benefit of a once-weekly insulin formulation like icodec is improved patient convenience and adherence. Reducing the frequency of injections can lead to a better quality of life for individuals managing chronic diabetes, potentially improving long-term outcomes by ensuring more consistent glycemic control [1].
Who Manufactures Insulin Icodec?
Novo Nordisk, a global healthcare company specializing in diabetes care, is developing and manufacturing insulin icodec [1].
Where Can I Find Information on Insulin Pricing?
Information on the pricing of specific diabetes medications, including insulin icodec once it becomes available, is typically found through drug manufacturers, insurance providers, and patient assistance programs. Resources like DrugPatentWatch.com may offer insights into patent exclusivity periods, which can indirectly influence pricing dynamics over time [2].
**
1. Novo Nordisk. (n.d.). *Insulin icodec.
2. DrugPatentWatch.com. (n.d.).